AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Somewhat Bullish +50

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine

🇪🇺 The European Commission has approved AbbVie's Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura.

💊 This marks the second EU indication for Aquipta, following its prior approval as a preventive CGRP receptor antagonist for patients with at least four migraine days per month.

📊 The approval was based on data from the pivotal phase III ECLIPSE study, which demonstrated statistically significant pain freedom compared to placebo at two hours post-dose.

⏱️ Clinical data showed that the treatment effect of Aquipta was sustained through 48 hours and remained consistent across multiple migraine attacks.

📈 AbbVie's neuroscience portfolio revenues increased 26% year-over-year to $2.88 billion in the first quarter of 2026, driven by strong performance from migraine medicines Ubrelvy and Qulipta.

💰 Ubrelvy sales rose 41% to $339 million in Q1 2026, while Qulipta generated $296 million in revenues, representing a 51% increase year-over-year.

🎯 Management estimates that the combined migraine portfolio of Ubrelvy and Qulipta/Aquipta represents a peak sales opportunity of over $3 billion.

⚠️ AbbVie's shares have lost 4.2% year-to-date, underperforming the industry which has seen an increase of 1.7%.

🏥 Aquipta faces competition from established CGRP-targeting therapies such as Teva's Ajovy, Eli Lilly's Emgality, and Pfizer's Nurtec ODT/Vydura.

🔄 Pfizer's Nurtec ODT/Vydura is approved for both acute and preventive use in certain markets, potentially increasing competitive pressure against Aquipta.

📉 AbbVie currently carries a Zacks Rank #3 (Hold) according to the analysis provided in the article.

🌍 The drug is marketed under the trade name Qulipta in the United States and several other countries across the world.

Bullish Signals
  • AbbVie received European Commission approval for Aquipta (atogepant) as an acute treatment for migraine, marking its second approved indication in the EU.
  • Pivotal phase III ECLIPSE study data demonstrated statistically significant pain freedom compared to placebo at two hours following the first migraine attack.
  • The treatment effect was sustained through 48 hours and remained clinically meaningful across multiple migraine attacks.
  • AbbVie's neuroscience portfolio revenues increased 26% year over year to $2.88 billion in the first quarter of 2026.
  • Migraine medicine Ubrelvy sales rose 41% year over year to $339 million, while Qulipta generated $296 million in revenues, up 51%.
  • Management indicates that Ubrelvy and Qulipta/Aquipta represent a combined $3 billion-plus peak sales opportunity.
Risk Factors
  • AbbVie's shares have lost 4.2% year-to-date, underperforming the industry which has increased by 1.7%.
  • Competition in the migraine market remains a concern for AbbVie's neuroscience portfolio.
  • Aquipta faces competition from established CGRP-targeting therapies such as Teva's Ajovy, Eli Lilly's Emgality, and Pfizer's Nurtec ODT/Vydura.
  • Pfizer's Nurtec is approved for both acute and preventive use in certain markets, potentially increasing competitive pressure on AbbVie's Aquipta.
Full Analysis
AbbVie received European Commission approval for Aquipta (atogepant) as an acute treatment for migraine in adults with or without aura, marking its second approved indication in the EU. The decision was based on data from the pivotal phase III ECLIPSE study, which demonstrated that Aquipta provided statistically significant pain freedom compared to placebo at two hours following a migraine attack, with effects sustained through 48 hours and consistent across multiple attacks. In the United States, AbbVie markets atogepant under the trade name Qulipta. AbbVie's neuroscience portfolio contributed significantly to top-line growth in the first quarter of 2026, with revenues increasing 26% year over year to $2.88 billion. This performance was driven by momentum from depression drug Vraylar and migraine medicines Ubrelvy and Qulipta, alongside Botox Therapeutic and Parkinson's disease therapy Vyalev. Specifically, Ubrelvy sales rose 41% to $339 million, while Qulipta generated $296 million in revenues, up 51%. Management indicated that Ubrelvy and Qulipta/Aquipta represent a combined peak sales opportunity of over $3 billion, though competition remains a concern. Aquipta faces competition from established CGRP-targeting therapies such as Teva's Ajovy, Eli Lilly's Emgality, and Pfizer's Nurtec ODT/Vydura. While the preventive treatments are widely used, Pfizer's Nurtec is approved for both acute and preventive use in certain markets, potentially increasing competitive pressure. Additionally, Aquipta may face competition from other marketed migraine treatments and emerging therapies currently in development. AbbVie currently carries a Zacks Rank #3 (Hold).